Paper: Pre- vs. Post-National Coverage Determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoietic-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA) (2009 ACCP/ESCP International Congress on Clinical Pharmacy (April 24

Sunday, April 26, 2009

Tanya Burton, PhD , Abt Bio-Pharma Solutions, Inc., Lexington, MA

Kay Larholt, ScD , Abt Bio-Pharma Solutions, Inc., Lexington, MA

Elizabeth Apgar, MPH , Abt Bio-Pharma Solutions, Inc., Lexington, MA

Chris Pashos, PhD , Abt Bio-Pharma Solutions, Inc., Lexington, MA

Brahim Bookhart, MBA, MPH , Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

Mitra Corral, MS, MPH , Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

Catherine T. Piech, MBA , Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

R. Scott McKenzie, MD , Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

47E Pre- vs. Post-National Coverage Determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoietic-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA)